Kazia Doses First Patient in Pediatric AT/RT Study
Sydney, Australia, September 10, 2026 Kazia Therapeutics Limited has announced that the first patient has been dosed in the...
BioMarin
Advertisement
BioMarin Reports Positive Phase 3 VOXZOGO Data
San Rafael, California, September 9, 2026 BioMarin Pharmaceutical Inc. has announced the publication of positive Phase 3 CANOPY-HCH-3 results...
AstraZeneca Tagrisso Combo Improves Lung Cancer PFS
Cambridge, UK, September 1, 2026 AstraZeneca has announced positive high-level results from the Phase III SANOVO trial, showing that...
Ascendis, BioMarin Reach Global YUVIWEL License Deal
COPENHAGEN, Denmark, August 31, 2026 Ascendis Pharma A/S and BioMarin Pharmaceutical Inc. have entered into a binding term sheet...
Masimo Gains CE Mark for AI-Powered Brain Monitor
Irvine, California, August 18, 2026 Masimo has received the CE Mark for its next-generation smartSedLine™ brain function monitor, introducing...
Advertisements
BioMarin to Acquire Alesta for Potential Oral HPP Treatments
SAN RAFAEL, Calif., August 18, 2026 BioMarin Pharmaceutical Inc. has entered into a definitive agreement to acquire Alesta Therapeutics,...
Waters Strengthens Clinical Diagnostics with Xevo XR Innovation
MILFORD, Mass., July 27, 2026 Waters Corporation has introduced the Xevo™ TQ Absolute XR IVD Mass Spectrometer, expanding its...
BioMarin Partners n-Lorem on First ReNU Syndrome Therapy
SAN RAFAEL, Calif. & SAN DIEGO, July 27, 2026 BioMarin Pharmaceutical Inc. and the n-Lorem Foundation have announced a...
BioMarin FDA Accepts VOXZOGO sNDA for Full Approval
SAN RAFAEL, Calif., July 13, 2026 BioMarin Pharmaceutical Inc. has reached a significant regulatory milestone after the U.S. Food...
BioMarin Reports Positive VOXZOGO and BMN 333 Data at ENDO 2026
SAN RAFAEL, Calif., June 16, 2026 BioMarin Pharmaceutical Inc. announced new clinical findings from its approved therapy VOXZOGO® (vosoritide)...
Advertisement
